venous distension, scattered basal rhonchi, and blood pressure of 90/60 mm Hg. Electrocardiography revealed atrial fibrillation with high ventricular response. Chest radiograph showed large cardiac silhouette with clear lung fields. Echocardiography confirmed a large anterior, posterior, and lateral pericardial effusion. Laboratory parameters were as follows: hemoglobin, 13.9 g/dL; leukocyte, 7200/μL; platelets count 1098,000/μL; international normalized ratio, 1.1; and activated partial thromboplastin time, 25 seconds. About 200 mL hemorrhagic pericardial fluid was aspirated by pericardiosentesis. Subsequently, 1400 mL hemorrhagic fluid was drained within 24 hours. Pericardial hemorrhage was considered to be associated with ET and the use of ASA therapy. Aspirin was stopped; hydroxyurea was increased to 2 g/d, and clopidogrel 75 mg/d was started as an antiaggregan therapy. At the follow-up, platelet count remained at 700,000/μL levels. Bleeding and thrombotic complications were not encountered during the next 16 months.
Pericardial hemorrhage that is related to the use of low-dose ASA in ET has not been reported previously. In literature, only 1 case was found with ET that developed nonhemorrhagic pericardial effusion secondary to pericarditis. 2 However, we did not detect the clinical and electrocardiographic manifestations of pericarditis in our patient. E ssential thrombocythemia (ET) is a clonal myeloproliferative disorder that causes thrombocytosis. The majority of the symptomatic patients present with microvascular disturbances. Essential thrombocythemia is characterized by an increased incidence of thrombosis, with arterial event more than venous events, and hemorrhagic complications, particularly related to high platelet counts. 1 Hemorrhagic diathesis is typically mucocutaneous and manifests with easy bruising, epistaxis, and gingival bleeding. Serious bleedings, including gastrointestinal or intracranial hemorrhages, are relatively infrequent. Administration of acetylsalicylic acid (ASA) enhances both minor and major bleedings.
A 57-year-old man with the history of stroke and diagnosis of ET was referred with dyspnea and chest pain. He has been using hydroxyurea 1.5 g/d and ASA 100 mg/d for 6 months. Physical examination revealed pulsus paradoxus (heart rate 100 beats/min), jugular Essential thrombocythemia is a clonal myeloproliferative disorder that causes thrombocytosis. Essential thrombocythemia is characterized by increased incidence of thrombosis with arterial event more than venous events and hemorrhagic complications. Acetylsalicylic acid enhances both minor and major bleedings. The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia. The patient was successfully managed with clopidogrel therapy during the 16 months follow-up without recurrent thrombotic or hemorrhagic events.
Keywords: essential thrombocythemia; pericardial hemorrhage; acetylsalicylic acid; clopidogrel
The major risk factor for hemorrhage in ET appears to be a platelet count exceeding 1500 × 10 9 /L, which may be accompanied by a reduction in higher molecular weight multimers of von Willebrand factor and hence acquired von Willebrand disease. 3 The use of low-dose ASA is recommended together with cytoreductive agents, such as hydroxyurea, anegralide and interferon, to prevent thrombotic events in high-risk patients. However, ASA may be contraindicated in some patients with bleeding history. There are few published data concerning the use of newer antiplatelet agents, such as clopidogrel in patients with ET. 4 Manoharan et al. have declared that ASA 100 mg/d is insufficient in some patients, and so they suggest increased doses of ASA with blood platelet lumi aggregometry technique. 5 This technique has also proved useful to optimize the clopidogrel therapy in patients who are unable to tolerate ASA. According to accepted expert view, clopidogrel can be administered to patients with ET who have major contraindications to ASA therapy. 6 In our patient, ASA was stopped due to the development of pericardial hemorrhage, and the dose of cytoreductive therapy was increased. Essentially, reduction of platelet count with cytoreductive therapy may be sufficient to decrease the risk of hemorrhage. However, in our patient, antiaggregant therapy could have not been ignored due to the history of stroke. Ticlopidine may be an alternative choice of therapy to reduce the risk of recurring thrombotic stroke in patients who experienced thrombotic stroke. It should be reserved for patients with ASA intolerance, but we did not use ticlopidine due to its adverse-effect risks such as hemolytic anemia, immune thrombocytopenia, thrombotic thrombocytopenic purpura, agranulocytosis, and bone marrow suppression. 7 Therefore, clopidogrel was commenced to prevent recurrent embolic event before discharge. Thrombotic and hemorrhagic complications were not seen during the 16-month follow-up.
In conclusion, ASA should be used carefully in patients with ET who have high platelet count because of increased risk of hemorrhagic complication. Clopidogrel may be an effective and safe alternative therapy for the prevention of bleeding and thrombotic complications in patients with ET who have ASA intolerance.
